Hepion pharmaceuticals announces pricing of $20.0 million private placement of convertible redeemable preferred stock

Edison, n.j., nov. 04, 2022 (globe newswire) -- hepion pharmaceuticals, inc. (nasdaq:hepa), a clinical stage biopharmaceutical company focused on artificial intelligence (“ai”)-driven therapeutic drug development for the treatment of fibrotic diseases, including non-alcoholic steatohepatitis (“nash”), hepatocellular carcinoma (“hcc”), and other chronic diseases, today announced that it has entered into a securities purchase agreement with certain institutional investors to purchase 1,900,000 shares of series f convertible redeemable preferred stock and 100,000 shares of series g convertible redeemable preferred stock.
HEPA Ratings Summary
HEPA Quant Ranking